吡非尼酮抑制TGF-β1诱导的人肺成纤维细胞表型转化

目的:研究吡非尼酮(PFD)是否抑制转化生长因子β1(TGF-β1)诱导的人肺成纤维细胞(HLFs)表型转化。方法:MTT法检测细胞存活率;Ed U法检测细胞的增殖能力;Transwell实验检测细胞的迁移和侵袭能力,Western blot法和细胞免疫荧光检测α-平滑肌肌动蛋白(α-SMA)的蛋白水平,实时荧光定量PCR检测α-SMA和Ⅰ、Ⅲ型胶原蛋白的mRNA表达水平。结果:不同浓度的吡非尼酮(0.1、0.2、0.3、0.5和0.8 mg/L)无明显的细胞毒性作用,后续实验应用0.2 mg/L为干预浓度。吡非尼酮(0.2 mg/L)预处理HLFs能明显地抑制TGF-β1诱导的细胞增殖、迁移和侵袭能力,下调Ⅰ、Ⅲ型胶原蛋白的mRNA表达水平(P0.05),并且干扰TGF-β1诱导的细胞骨架重组和表型转化,使α-SMA的mRNA和蛋白水平均下降(P0.05)。结论:吡非尼酮能有效地抑制TGF-β1所诱导的HLFs细胞功能和表型转化。

Pirfenidone inhibits TGF-β1-induced differentiation of myofibroblast in human lung fibroblast populations

ATM: To investigate the effect of pirfenidone on transforming growth factor-β1 (TGF-β1)-induced fibroblast-to-myofibroblast transition in vitro. METHODS: The cell viability was measured by MTT assay. The proliferation of human lung fibroblasts (HLFs) was detected by EdU incorporation. Migratory and invasive abilities were measured by Boyden chamber assay. The α-smooth muscle actin (α-SMA) protein expression was determined by Western blot and immunofluorescence. The mRNA expression of α-SMA and type Ⅰ and Ⅲ collagens was evaluated by RT-qPCR. RESULTS: Pirfenidone at different concentrations (0.1, 0.2, 0.3, 0.5 and 0.8 mg/L) had no cytotoxic effect on the HLFs, and pirfenidone at 0.2 mg/L was used for the intervention. Pretreatment of the HLFs with 0.2 mg/L pirfenidone prior to TGF-β1 not only markedly suppressed the changes of proliferation, migration, invasion and reorganization of actin cytoskeleton in the HLFs (P<0.01﹚,but also down-regulated the expression of α-SMA and type C and Ⅲ collagens triggered by TGF-β1 ﹙P<0.05﹚.CONCLUSION: Pirfenidone has an inhibitory effect on TGF-β1-induced activated cell functions and fibroblast-to-myofibroblast transition in HLFs.